Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, -Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. Journal Abstract

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, -Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Publication Date: 2024 Aug 22

Full Text Sources

Authors

James Chih-Hsin Yang; Dae Ho Lee; Jong-Seok Lee; Yun Fan; Filippo de Marinis; Eiji Iwama; Takako Inoue; Jerónimo Rodríguez-Cid; Li Zhang; Cheng-Ta Yang; Emmanuel de la Mora Jimenez; Jianying Zhou; Maurice Pérol; Ki Hyeong Lee; David Vicente; Eiki Ichihara; Gregory J Riely; Yiwen Luo; Diana Chirovsky; M Catherine Pietanza; Niyati Bhagwati; Shun Lu

Abstract

OBJECTIVE

Epidermal growth factor receptor () tyrosine kinase inhibitors (TKIs) are standard first-line therapy for -mutant, metastatic non-small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum-based chemotherapy with or without pembrolizumab for TKI-resistant, -mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837).

Source

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pub Types(s)

Journal Article

Language

English

PubMed ID

39173098